RADX

Radiopharm Theranostics Limited

Price Chart

Latest Quote

$4.30

-0.03 (-0.69%)

Current Price

Previous Close	$4.33
Open	$4.29
Day High	$4.33
Day Low	$4.11
Volume	28,599

Fetched: 2026-07-14T23:35:18

Stock Information

Note: Financial values converted from AUD to USD

Shares Outstanding	7.88M
Cash Equivalents	$24.08M
Revenue	$11.36M
Net Income	$-32.50M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$33.90M
EPS (TTM)	$-3.56
Exchange	NCM

🌐 Visit Website

Recent Price History

Date	Close	Volume
2026-07-17	$4.43	31,900
2026-07-16	$4.29	19,700
2026-07-15	$4.33	41,700
2026-07-14	$4.30	28,700
2026-07-13	$4.33	8,300
2026-07-10	$4.37	12,500
2026-07-09	$4.28	20,400
2026-07-08	$4.33	11,000
2026-07-07	$4.24	19,800
2026-07-06	$4.35	7,000
2026-07-02	$4.37	18,000
2026-07-01	$4.25	25,900
2026-06-30	$4.19	33,700
2026-06-29	$4.13	14,700
2026-06-26	$4.02	60,500
2026-06-25	$4.33	24,700
2026-06-24	$4.14	29,800
2026-06-23	$4.38	4,100
2026-06-22	$4.31	12,400
2026-06-18	$4.45	17,200

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

📰 Latest News

Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference

MarketBeat • 2026-04-29T09:04:38Z

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

Insider Monkey • 2026-04-28T17:29:48Z

Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Proactive • 2026-03-26T23:20:00Z

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

MarketBeat • 2026-03-25T08:32:23Z

Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks

MarketBeat • 2026-03-25T07:33:01Z

Favourable Signals For Radiopharm Theranostics: Numerous Insiders Acquired Stock

Simply Wall St. • 2025-12-22T00:57:27Z

Radiopharm (RADX) Sees Slight Pessimism From Analysts

Insider Monkey • 2025-12-15T17:35:45Z

Top Midday Gainers

MT Newswires • 2025-12-15T17:28:27Z

Radiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell

MT Newswires • 2025-10-20T12:23:51Z

Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial

TipRanks • 2025-10-02T12:15:46Z

Period:

Income Statement (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Revenue
Reconciled Cost Of Revenue	$2,507,952	$0	$0	-
Cost Of Revenue	$2,507,952	$0	$0	-
Total Revenue	$2,535,358	$208,798	$204,005	$6,162
Operating Revenue	$2,535,358	$208,798	$204,005	$6,162
Expenses
Interest Expense	$45,566	$448,600	$60,073	$6,524,136
Total Expenses	$26,707,247	$26,148,289	$22,317,326	$13,903,554
Other Income Expense	$-2,743,381	$-7,294,107	$-2,052,566	$-717,669
Net Non Operating Interest Income Expense	$232,439	$-157,480	$41,130	$-6,524,136
Total Other Finance Cost	$341,767	$-255,892	-	-
Interest Expense Non Operating	$45,566	$448,600	$60,073	$6,524,136
Operating Expense	$24,199,296	$26,148,289	$22,317,326	$13,903,554
Other Operating Expenses	$-6,537,258	$-901,945	$-4,129,149	$1,121,205
General And Administrative Expense	$11,531,665	$10,935,657	$10,649,907	$7,823,702
Other Non Operating Income Expenses	-	$-5,280,706	$4,129,149	$-717,669
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-26,754,906	$-33,458,320	$-24,151,276	$-21,170,175
Net Interest Income	$232,439	$-157,480	$41,130	$-6,524,136
Interest Income	$619,773	$35,227	$101,204	-
Normalized Income	$-24,834,540	$-28,352,445	$-22,714,480	$-20,667,807
Net Income From Continuing And Discontinued Operation	$-26,754,906	$-33,458,320	$-24,151,276	$-21,170,175
Total Operating Income As Reported	$-26,637,265	$-32,942,479	$-24,064,683	-
Net Income Common Stockholders	$-26,754,906	$-33,458,320	$-24,151,276	$-21,170,175
Net Income	$-26,754,906	$-33,458,320	$-24,151,276	$-21,170,175
Net Income Including Noncontrolling Interests	$-26,754,906	$-33,458,320	$-24,151,276	$-21,170,175
Net Income Continuous Operations	$-26,754,906	$-33,458,320	$-24,151,276	$-21,170,175
Pretax Income	$-26,682,830	$-33,391,078	$-24,124,756	$-21,139,196
Special Income Charges	$-2,839,774	$-7,360,372	$-1,873,059	-
Interest Income Non Operating	$619,773	$35,227	$101,204	-
Operating Income	$-24,171,889	$-25,939,491	$-22,113,321	$-13,897,391
Depreciation Amortization Depletion Income Statement	$5,115	$5,257	$4,573	$2,080,444
Depreciation And Amortization In Income Statement	$5,115	$5,257	$4,573	$2,080,444
Depreciation Income Statement	$5,115	$5,257	$4,573	$817
Gross Profit	$27,406	$208,798	$204,005	$6,162
Amortization Of Intangibles Income Statement	-	$2,176,228	$2,295,708	$2,079,627
Per Share
Diluted EPS	$-3.68	$-25.98	$-22.38	$-31.99
Basic EPS	$-3.68	$-25.98	$-22.38	$-31.99
Other
Tax Effect Of Unusual Items	$-823,014	$-2,188,232	$-615,770	$-215,301
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-23,888,769	$-25,643,114	$-22,007,545	$-11,816,948
Total Unusual Items	$-2,743,381	$-7,294,107	$-2,052,566	$-717,669
Total Unusual Items Excluding Goodwill	$-2,743,381	$-7,294,107	$-2,052,566	$-717,669
Reconciled Depreciation	$5,115	$5,257	$4,573	$2,080,444
EBITDA (Bullshit earnings)	$-26,632,149	$-32,937,222	$-24,060,111	$-12,534,616
EBIT	$-26,637,265	$-32,942,479	$-24,064,683	$-14,615,060
Diluted Average Shares	$4,850,564	$898,891	$753,184	$461,736
Basic Average Shares	$4,840,459	$898,891	$753,184	$461,736
Diluted NI Availto Com Stockholders	$-26,754,906	$-33,458,320	$-24,151,276	-
Tax Provision	$72,076	$67,242	$26,519	$30,980
Gain On Sale Of Ppe	$0	$-1,177,720	$0	-
Restructuring And Mergern Acquisition	$2,839,774	$6,182,651	$1,873,059	-
Gain On Sale Of Security	$96,393	$66,265	$-179,507	$-717,669
Research And Development	$19,199,772	$16,109,320	$15,791,995	$2,878,202
Selling General And Administration	$11,531,665	$10,935,657	$10,649,907	$7,823,702
Other Gand A	$3,073,596	$2,249,476	$3,760,915	$1,374,375
Insurance And Claims	$73,799	$250,652	$478,273	-
Salaries And Wages	$8,384,270	$8,435,529	$6,410,719	$6,449,327
Impairment Of Capital Assets	-	$1,031,953	$2,163,143	-
Amortization	-	$2,176,228	$2,295,708	$2,079,627

Fetched: 2026-07-14

Balance Sheet (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Assets
Net Tangible Assets	$-1,243,750	$-14,628,934	$-9,878,407	$4,805,953
Total Assets	$60,346,015	$50,266,097	$52,298,979	$58,182,464
Total Non Current Assets	$32,536,381	$34,322,855	$40,924,962	$39,157,690
Investmentin Financial Assets	$0	$27,912	-	-
Goodwill And Other Intangible Assets	$32,499,073	$34,252,521	$40,849,371	$39,128,677
Other Intangible Assets	$32,499,073	$34,252,521	$40,849,371	$39,128,677
Current Assets	$27,809,635	$15,943,242	$11,374,017	$19,024,775
Other Current Assets	$235,219	$201,113	$92,897	$159,666
Assets Held For Sale Current	$0	$2,091,684	-	-
Receivables	$7,257,037	$689,005	$3,117,653	$39,412
Other Receivables	$159,464	$128,690	$3,044,589	-
Taxes Receivable	$7,097,573	$560,315	-	-
Cash Cash Equivalents And Short Term Investments	$20,317,378	$12,961,440	$8,163,468	$18,825,696
Cash And Cash Equivalents	$20,317,378	$12,961,440	$8,163,468	$18,825,696
Cash Financial	$20,317,378	$12,961,440	$8,163,468	$18,825,696
Other Non Current Assets	-	$27,912	$27,912	$27,912
Accounts Receivable	-	$560,315	$73,064	$39,412
Gross Accounts Receivable	-	$560,315	$73,064	$39,412
Liabilities
Total Liabilities Net Minority Interest	$30,430,515	$31,179,302	$20,494,203	$14,247,835
Total Non Current Liabilities Net Minority Interest	$20,010,457	$18,915,141	$11,263,028	$8,750,223
Other Non Current Liabilities	$20,010,457	$18,915,141	$11,144,961	$8,643,847
Tradeand Other Payables Non Current	$0	$0	$118,067	$106,376
Non Current Deferred Liabilities	$0	$0	-	-
Current Liabilities	$10,420,058	$12,264,161	$9,231,175	$5,497,611
Other Current Liabilities	$2,387,368	$2,765,547	$5,457,192	$3,930,059
Current Deferred Liabilities	$1,200,580	$1,643,908	-	-
Payables And Accrued Expenses	$6,518,033	$7,575,740	$3,572,301	$1,502,559
Payables	$4,598,654	$6,403,148	$3,572,301	$1,502,559
Other Payable	$169,516	$1,913,214	$1,509,271	$672,443
Accounts Payable	$4,429,137	$4,489,934	$2,063,030	$830,117
Equity
Common Stock Equity	$31,255,323	$19,623,586	$30,970,963	$43,934,630
Total Equity Gross Minority Interest	$29,915,500	$19,086,795	$31,804,776	$43,934,630
Stockholders Equity	$31,255,323	$19,623,586	$30,970,963	$43,934,630
Other Equity Interest	$592,802	$592,802	$1,497,848	-
Gains Losses Not Affecting Retained Earnings	$9,152,829	$26,467,149	$7,230,100	$4,904,127
Other Equity Adjustments	$9,152,829	$26,467,149	$7,230,100	$4,904,127
Retained Earnings	$-101,690,705	$-77,690,858	$-45,603,142	$-21,508,735
Other
Ordinary Shares Number	$1,650,233,383	$321,238,604	$250,691,010	$195,219,832
Share Issued	$1,650,233,383	$321,238,604	$250,691,010	$195,219,832
Tangible Book Value	$-1,243,750	$-14,628,934	$-9,878,407	$4,805,953
Invested Capital	$31,255,323	$19,623,586	$30,970,963	$43,934,630
Working Capital	$17,389,577	$3,679,080	$2,142,842	$13,527,163
Total Capitalization	$31,255,323	$19,623,586	$30,970,963	$43,934,630
Minority Interest	$-1,339,823	$-536,792	$833,813	-
Capital Stock	$123,200,398	$70,254,493	$67,846,157	$60,539,238
Common Stock	$123,200,398	$70,254,493	$67,846,157	$60,539,238
Current Deferred Revenue	$1,200,580	$0	-	-
Pensionand Other Post Retirement Benefit Plans Current	$314,077	$278,967	$201,682	$64,993
Current Accrued Expenses	$1,919,379	$1,172,592	-	-
Investments And Advances	$0	$27,912	-	-
Net PPE	$37,308	$42,423	$47,680	$1,101
Foreign Currency Translation Adjustments	-	$-379,832	-	-
Available For Sale Securities	-	$27,912	-	-
Gross PPE	-	$42,423	$47,680	$1,101
Machinery Furniture Equipment	-	$42,423	$47,680	$1,101

Fetched: 2026-07-14

Cash Flow Statement (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Free Cash Flow
Free Cash Flow	$-25,570,774	$-16,032,332	$-17,258,027	$-26,693,394
Operating Activities
Cash Flowsfromusedin Operating Activities Direct	$-25,570,774	$-16,032,332	$-16,189,936	$-6,919,024
Classesof Cash Receiptsfrom Operating Activities	$3,735,938	$3,567,302	$1,289,202	$-6,919,024
Other Cash Paymentsfrom Operating Activities	-	$3,385,555	$1,085,197	-
Other Cash Receiptsfrom Operating Activities	-	$3,385,555	$1,085,197	-
Investing Activities
Investing Cash Flow	$1,235,502	$-223,292	$-1,068,091	$-19,796,119
Cash Flow From Continuing Investing Activities	$1,235,502	$-223,292	$-1,068,091	$-19,796,119
Net Other Investing Changes	$-856,182	$-223,292	-	$-27,912
Capital Expenditure	-	-	$-1,068,091	$-19,774,370
Financing Activities
Issuance Of Capital Stock	$37,665,132	$20,686,292	$7,028,508	$48,845,160
Financing Cash Flow	$31,701,589	$21,071,066	$6,432,064	$45,433,056
Cash Flow From Continuing Financing Activities	$31,701,589	$21,071,066	$6,432,064	$45,433,056
Net Other Financing Charges	$-4,637,746	$-1,151,888	$-596,444	$-3,370,934
Net Common Stock Issuance	$37,665,132	$20,686,292	$7,028,508	$48,845,160
Common Stock Issuance	$37,665,132	$20,686,292	$7,028,508	$48,845,160
Repurchase Of Capital Stock	-	$-1,070,247	$-596,444	$-3,370,934
Other
Repayment Of Debt	$-1,325,797	$-3,605,471	$0	$-48,147
Issuance Of Debt	$0	$5,142,132	$0	$6,978
End Cash Position	$20,317,378	$12,961,440	$8,163,468	$18,825,696
Beginning Cash Position	$12,961,440	$8,163,468	$18,825,696	$18,904
Effect Of Exchange Rate Changes	$-10,379	$-17,470	$163,735	$88,879
Changes In Cash	$7,366,317	$4,815,442	$-10,825,963	$18,717,913
Net Issuance Payments Of Debt	$-1,325,797	$1,536,662	$0	$-41,169
Net Long Term Debt Issuance	$-1,325,797	$1,536,662	$0	$-41,169
Long Term Debt Payments	$-1,325,797	$-3,605,471	$0	$-48,147
Long Term Debt Issuance	$0	$5,142,132	$0	$6,978
Net Intangibles Purchase And Sale	$2,091,684	$0	$-1,036,477	$-19,772,452
Net PPE Purchase And Sale	$0	$0	$-31,614	$-1,918
Purchase Of PPE	$0	$0	$-31,614	$-1,918
Taxes Refund Paid Direct	$0	$3,385,555	$1,085,197	-
Interest Received Direct	$558,446	$35,227	$101,204	-
Classesof Cash Payments	$-29,865,158	$-19,634,861	$-17,580,342	-
Paymentsto Suppliersfor Goodsand Services	$-29,865,158	$-19,634,861	$-17,580,342	-
Receiptsfrom Customers	$3,735,938	$181,747	$204,005	$-6,919,024
Common Stock Payments	-	$-1,070,247	$-596,444	$-3,370,934
Purchase Of Intangibles	-	-	$-1,036,477	$-19,772,452
Interest Received Cfi	-	-	-	$6,162

Fetched: 2026-07-14